Tepotinib
Tepmetko (tepotinib) is a small molecule pharmaceutical. Tepotinib was first approved as Tepmetko on 2021-02-03. The pharmaceutical is active against hepatocyte growth factor receptor. Tepmetko's patents are valid until 2030-03-19 (FDA).
Trade Name | Tepmetko |
---|---|
Common Name | Tepotinib |
Indication | |
Drug Class | Tyrosine kinase inhibitors |